Getting Up to Date with What Works: A Systematic Review on the Effectiveness and Safety of Task Sharing of Modern Methods in Family Planning Services

Table 1

Basic characteristics of studies included in the review.

1^st author, year	Study site	Study design	Study size, population	Interventions	Outcomes reported
Anitra Beasley, [40]	Health facilities and community, New York, USA	RCT	132 years	Self-injection compared to facility-based administration of DMPA-SC	12-month contraceptive continuation: 47% and 48% for the self and clinic administration groups (). MPA levels in serum: similar in both groups ( pg/ml vs. ( pg/ml)
Holly Burke, [39]	Health facilities and community, rural Malawi, Africa	RCT	731 years	Self-injection compared to facility-based administration of DMPA-SC	12-month contraceptive continuation: 73% in the self-injection group and 45% in the provider-administered group (log-rank ). Side effects: reported by ten women (20 events) in the self-administered group and 17 women (28 events) in the provider-administered group ()
Jane Cover, [37]	Health facilities and community, Uganda, Africa	NRCT	1161 years	Self-injection of DMPA-SC compared to facility-based administration of DMPA-IM	12-month contraceptive continuation: 0.81 (95% CI.78–.84) in the DMPA-SC group, 0.65 (95% CI 61–.69) in DMPA-IM group (). Side effects, adverse events: greater percentage of reports among the DMPA-IM group, more injection site reactions among the DMPA-SC group
Jane Cover, [38]	Health facilities and community, Senegal, Africa	NRCT	1299 years	Self-injection of DMPA-SC compared to facility-based administration of DMPA-IM	12-month contraceptive continuation: 80.2% in the self-injecting group, 70.4% in the provider-administered group (). Side effects, adverse events: fewer reports among the self-injection group compared to the provider-administered group
Julia E Kohn, [41]	Health facilities and community, Texas and New Jersey	RCT	401 years	Self-injection compared to facility-based administration of DMPA-SC	12-month contraceptive continuation: 69% among self-injectors vs. 54% among the provider-administered group (). Side effects: no serious side effects reported. Satisfaction: 87% among self-injectors vs. 92% among the provider-administered group
Mark A Barone, [36]	Health facilities, Tanzania, Africa	RCT		Tubal ligation performed by associate clinicians (CO) versus advanced associate clinicians (AMO)	Rate of major adverse effects: 0% in the CO group, 0.1% in the AMO group (RD-0.1%, 95% CI -0.3%-0.1%). No differences in participant satisfaction between the groups